血清OPG、RANKL在心力衰竭与骨质疏松症中临床意义

影影 梁, 秀华 李, 国玉 王, 梦 闫, 慧 刘

摘要


骨保护素（osteoprotegerin，OPG），是肿瘤坏死因子受体（tumor necrosis factor receptor，TNFR）超家族的非典型成员，具有抑制过度骨吸收、增加骨量来保护骨骼及调节骨密度的作用，核因子 -kB 受体活化因子配体（Receptor Activator for Nuclear actor-κB Ligand，RANKL），也称肿瘤坏死因子相关激活诱导细胞因子（TRANCE），是肿瘤坏死因子（TNF）配体家族的成员，是骨吸收的重要生理和病理介质。近年来的研究发现，OPG/RANKL/RANK 通路不仅参与了骨质疏松症（osteoporosis，OP）的发病机制，在心力衰竭（heart failure，HF）中也起着重要作用。因此，论文通过相关领域的进展进行综述，从而对血清 OPG、RANKL 在心衰及骨质疏松症的诊断及预后提供新思路。

关键词


慢性心力衰竭；骨质疏松症；骨保护素；核因子 κB 受体活化因子配体

全文:

PDF

参考


Habibie, H. The role of osteoprotegerin (OPG) in fibrosis: its potential as a biomarker and/or biological target for the treatment of fibrotic diseases[J]. Pharmacol Ther,2021(228):107941.

邓林华.心脏代谢疾病生物标志物骨保护素的中西医研究进展 [J].中西医结合心脑血管病,2020,18(24):4165-4169.

Walsh, M C, Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond[J]. Front Immunol,2014(5):511.

Dutka, M. Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases[J]. Heart Fail Rev,2021(5):595.

Hikita, A. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand[J]. Biol Chem,2006,281(48):36846.

宋菊香.血清OPG、ALP及NT-proBNP对血液透析患者并发心血管疾病的预测价值[J].国际检验医学,2021,42(10):1200-1203+1207.

Elango, J, B Bao, W Wu. The hidden secrets of soluble RANKL in bone biology[J]. Cytokine,2021(144):155559.

于冬冬.辛伐他汀通过NF-κB通路抑制破骨细胞的分化[J].中国医科大学学报,2020,49(3):198-202+208.

Berezin, A E. The utility of biomarker risk prediction score in patients with chronic heart failure[J]. Clin Hypertens,2015(22):3.

Ueland, T. Dysregulated osteoprotegerin/RANK ligand/ RANK axis in clinical and experimental heart failure[J]. Circulation,2005,111(19):2461.

Ueland, T. TNF revisited: osteoprotegerin and TNF-related molecules in heart failure[J]. Curr Heart Fail Rep,2012,9(2):92-100.

Foldes, G, S D. Anker and S. von Haehling, Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure[J].Card Fail,2009,15(6):551.

Dutka, M. Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases[J]. Heart Fail Rev,2021(5):45-46.

Bansal, S S. Activated T Lymphocytes are essential drivers of pathological remodeling in ischemic heart failure[J]. Circ Heart Fail, 2017,10(3):3688.

刘倩茹,李 . 保护素在冠心病发生、发展及 后中的研究展[J].中西医结合心 血管病,2020,18(7):1078-1082.

Roysland, R. Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial[J]. Am Heart,2010,160(2):286-293.

DAssante, R. Myocardial expression of somatotropic axis, adrenergic signalling, and calcium handling genes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction[J]. ESC Heart Fail,2021,8(2):1681-1686.

李徽. 保护素和 岛素样生长因子在冠心病心力衰竭表 意义[J].当代医学,2015,21(12):5-6.

Ozkalayci, F. The role of osteoprotegerin as a cardioprotective versus reactive inflammatory marker: The chicken or the egg paradox[J]. Balkan Med,2018,35(3):225-232.

吕小棉.血清OPG/RANKL与慢性心力衰竭患 BNP及hs-CRP的相关性分析[D].石家庄:河北医科大学,2017.

Hamoudi, D. Muscle weakness and selective muscle atrophy in osteoprotegerin-deficient mice[J]. Hum Mol Genet,2020,29(3):483-494.

Belibasakis, G N, N Bostanci. The RANKL-OPG system in clinical periodontology[J].Clin Periodontol,2012,39(3):239-248.

宋红.不同性别及年 因素对原发性 质疏松症 代谢指标、血清 保护素及 密度影响的研究[ J ] .中国 质疏松,2015,21(10):1161-1164.

Leistner, D M. Elevated levels of the mediator of catabolic bone remodeling RANKL in the bone marrow environment link chronic heart failure with osteoporosis[J]. Circ Heart Fail,2012,5(6):769-777.

Loncar, G. Relationship between RANKL and neuroendocrine activation in elderly males with heart failure[J].Endocrine,2010,37(1):148-156.

王斌.Wnt/β-catenin、BMP-2/Runx2/Osterix、OPG/RANKL、LGR4/RANKL 的相关因子在绝经后 质疏松性 折中的表 [J].中国 质疏松,2020,26(11):1577-1583+1658.




DOI: https://doi.org/10.12346/pmr.v3i6.4899

Refbacks

  • 当前没有refback。